Glaukos falls on wider-than-expected Q4 loss

Glaukos

21/02/2025 14:07

** Shares of medtech firm Glaukos  GKOS.N  fall 11.2% to
$139.7 premarket
    ** Co on Thursday posted Q4 net loss of $22.2 mln, vs Wall
Street estimate of $20.8 mln loss, as per data compiled by LSEG 
    ** GKOS reported Q4 revenue of $105.5 mln, vs est. of $100.7
mln  
    ** Co forecast 2025 sales in the range of $475 million to
$485 million compared with expectation of $479.8 mln
    ** GKOS's lead product is the iStent inject W, a device used
to treat glaucoma, an eye condition that damages the optic nerve
    ** Stock has risen 75.7% in the past 12 months

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))